Molecule is claimed to be made from "natural ingredients" such as dandelion root and fennel seed, but investigations tell a different story ...

New survey data shows 37 percent of US adults are currently classed as obese, down from a record high of 39.9 percent in 2022 ...

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...

Novo Nordisk attempts to acquire weight-loss drug company Metsera during government shutdown, potentially avoiding FTC ...

Ozempic, Mounjaro and Wegovy are now cultural symbols of weight loss. These medications help control blood sugar and aid ...

Plus, the Trump administration is expected to release finalized Medicare payment rules for doctors and hospitals as soon as ...

Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

A new Gallup poll indicates that the obesity rate among U.S. adults has declined over the past three years as the number of ...

A groundbreaking study has compared the three top weight loss medications on the market, which has produced some surprising ...

LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive ...

The New York-based biotech is at the centre of a bidding war between Novo Nordisk and Pfizer, both vying for access to its pipeline of experimental treatments as competition intensifies in the booming ...